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Abstract
Background: Stromal cell-derived factor-1 (SDF-1)/CXC Chemokine receptor 4 (CXCR4) is an important cytokine, with multiple func-
tions, which plays a crucial role in the recruitment of multiple stem cell types in the defect sites of central nervous system (CNS).
Various strategies have been managed to improve functional recovery after spinal cord injury (SCI). One of these strategies is the
use of factors to limit damage and increase recovery.
Objectives: In this study we investigated the effect of SDF-1 in spinal cord injury repair in a rat model.
Materials and Methods: Adult male Wistar rats were randomly divided to four groups (n = 5) as follows: Sham, SCI, SDF-1 and Vehicle.
Spinal cord injury model was created by contusion of T8-T9 by clips and SDF-1 infusion pump implanted in the neck region. One
week after injury, 5-Bromo-20-Deoxyuridine (BrdU) was injected to trace the proliferative cells. Basso-Beattie-Bresnahan (BBB) test
was performed to evaluate locomotor activity following SCI. Immunohistochemistry test was performed to determine proliferating
cells, and real time polymerase chain reaction (PCR) was performed to detect the CXCR4 cells in tissue.
Results: Significant improvements in locomotor function were detected in the SDF-1 group compared with the SCI and vehicle
groups (P < 0.05). The results showed that SDF-1 treatment increased proliferative cells at the spinal cord injury site. Real time
PCR revealed that these proliferative cells are CXCR4 positive that intake Bromodeoxyuridine (Brdu).
Conclusions: These results showed that the administration of SDF-1a increases the number of proliferating cells in the injured area
in the spinal cord and improves functional recovery.
Keywords: SDF-1, CXCR4, Spinal Cord Injury, Rat
1. Background
Spinal cord injury (SCI) is a severe condition, which
is characterized by a complex of motor, sensory and neu-
rological dysfunctions, which induces inflammatory re-
sponses at the lesion site. These responses attract in-
flammatory cells to the damaged area and lead to the in-
crease of chemokines in the plasma (1). Membranous CXC
Chemokine receptor 4 (CXCR4) and its ligand, stromal-
derived factor-1 (SDF-1, namely CXCL12), are members of
the chemokine family, which have a critical role in em-
bryo development, immune responses, inflammatory re-
actions and hematopoietic system modulation (2, 3). Ad-
ditionally, SDF-1 is a chemokine, which mediates develop-
ment of neural tissues and early spinal cord progenitor cell
differentiation (4). There is good evidence that the admin-
istration of growth factors, such as SDF-1a, can stimulate
stem cells to repopulate damaged CNS regions (5). Stromal-
derived factor-1 is fundamental to central nervous system
development, homeostasis and traumatic injury (6). The
SDF-1/CXCR4 axis plays an important role in the mobiliza-
tion of progenitor stem cells during embryogenesis and
tissue regeneration (7). Also evidence has indicated that
SDF-1/CXCR4 axis plays a crucial role in the recruitment of
bone mesenchymal stem cells (BMSCs) to lesion sites in an-
imal models (8). There exists preliminary data indicating
that SDF-1a might also be involved in the pathophysiology
of SCI. It has been reported that the expression of SDF-1a
was positively correlated with the lesion grade after SCI (9),
and increased significantly in spinal cord lesions (10). It
was demonstrated that SDF-1a and its receptor CXCR4, are
upregulated in the injured spinal cord (5). Recent studies
have indicated that SDF-1a signaling system may be impor-
tant for regulating the inflammatory response after SCI (11).
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2. Objectives
In this study we investigated the regeneration effects
of continuous administration of SDF-1a in a spinal cord in-
jury model in rats.
3. Materials and Methods
3.1. Animals and Experimental Design
Twenty adult male Wistar rats (approximately 250 - 300
g) were used in this study; all animal procedures were
approved by the ethical guidelines for the care of labora-
tory animals of the research center of Iran University of
Medical Sciences. The rats were kept in standard cages; at
22°C with a 12:12 light/dark cycle, in a controlled environ-
ment with free access to food and water. Animals were ran-
domly divided to four groups (n = 5): Sham group, received
laminectomies; SCI group, spinal cord injury; SDF-1 group,
spinal cord injury with infusion pump for SDF-1; and vehi-
cle group, spinal cord injury with infusion pump for PBS.
3.2. Spinal Cord Injury Procedure
Rats were deeply anesthetized via an intraperitoneal
injection of ketamine and xylazine (80/5 mg/kg). The an-
imals were positioned in a prone and surgery was per-
formed under sterile conditions. Skin was shaved and dis-
infected with povidone iodine solution. Skin incision and
blunt dissection of the muscle layers over the area was per-
formed. After removing the dorsal processes of the 9th and
10th thoracic vertebrae, spinal cord compression injury
was performed at the region of the 9 - 10th thoracic seg-
ment by 50 g weight clips for one minute (12, 13). The ani-
mals received postoperative care including Ringer’s lactate
solution (1 mL, subcutaneously) for seven days and peni-
cillin/streptomycin (intramuscularly, Invitrogen) for three
days. Additionally, bladders were massaged twice a day
until bladder reflex returned. Bromodeoxyuridine was in-
jected intraperitoneally, 24 hour after surgery (50 mg/kg)
for seven days.
3.3. Implantation of Infusion Pump for Intrathecal Application
Prior to SCI, the animals were placed in a stereotaxic
unit. After neck hyper flexion, a midline incision was made
in the skin of the nuchal crest, then surrounded muscles
were carefully dissected and the cistern magna was ex-
posed, by making 2 mm incision in dura, and a catheter
(Spectranetics, USA) was inserted in the incision (at the
first cervical vertebra). The incision was subsequently su-
tured. Seven days after the lesion, for continuous intrathe-
cal SDF-1 administration, an infusion pump (Model 2004,
Alzet, USA) was implanted subcutaneously in the neck re-
gion filled with 500 ng/mL of SDF-1 dissolved in saline with
flow rate of 0.25 m/hour and connected to the catheter (5).
3.4. Tissue Preparation and Immunohistochemistry (BrdU La-
beling)
At the end of the experiment, the animals were deeply
anesthetized with ketamine and xylazine and were per-
fused transcardially with 150 - 200 mL PBS followed by 100
mL paraformaldehyde 4%. The spinal cord was dissected
and maintained 48 hours in paraformaldehyde 4%. Fixed
samples were kept to histological processing and finally
tissue specimens were embedded in paraffin. To identify
the proliferating cells, the spinal cord sections (5µm) were
treated with 2N HCl at 37°C for one hour and neutralized
twice with 0.1 M borate, pH 8.5 for 10 minutes. The sec-
tions were then washed three times with washing solution
(PBS with 0.2% TritonX-100) and incubated in the block-
ing solution (PBS containing 3% normal goat serum and
0.2% TritonX-100) for 30 minutes at room temperature. Af-
ter rinsing, the sections were incubated overnight at 4°C
with primary antibody (rat anti-Brdu). The sections were
washed with the washing solution and incubated with
the corresponding secondary antibody for two hours at
room temperature and were mounted. The Brdu positive
cells were counted manually after the section was digitally
recorded using a microscope (Olympus AX70), Olympus
DP11 microscope digital camera and OLYSIA autobioreport
software (Olympus optical Co. Ltd. Japan). Cell numbers
are expressed as mm2 (14).
3.5. Real Time Reverse Transcriptase-Polymerase Chain Reac-
tion
For analysis of CXCR4 mRNA level, total mRNA was iso-
lated from cells with Trizol reagent (Invitrogen), accord-
ing to the manufacturer’s instructions. mRNA was reverse-
transcribed with a cDNA synthesis kit (Roche, USA). The
CXCR4 mRNA levels were determined by Real-Time poly-
merase chain reaction (RT-PCR), using an ABI PRISMs 7000
Sequence Detection System (ABI, USA). Twenty-five micro-
liter reaction mixtures containing 12.5 µL SYBR Green PCR
master mix and 10 ng of cDNA template and primers (5’-
CCTCGGGGCCAAATTCAAGA -3’ forward and 5’- GAAGAGT-
GTCCACCCCGTTT -3’ reverse) for CXCR4 was used. The
threshold cycle (Ct), i.e. the cycle number at which the
amount of amplified gene of interest reached a fixed
threshold, was subsequently determined. Relative quan-
tification of CXCR4 mRNA expression was calculated with
the comparative Ct method (15).
3.6. Locomotor Function
Basso, Beattie and Bresnahan (BBB) locomotion rating
scale, is the most commonly used test of locomotor func-
tion in spinal cord injured rats. Briefly, the rats were placed
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in an open field box, and the dual hind limb motor func-
tion was quantified using a scale ranging from 0 to 21,
where 0 corresponds to no locomotor activity and 21 cor-
responds to normal performance. The test was carried out
one day before and after the surgery, and then weekly tests
were performed for five weeks to analyze locomotor recov-
ery of spinal cord injury after transplantation (16).
3.7. Statistical Analysis
One-way analysis of variance (ANOVA) followed by post
hoc Tukey test was used to determine statistical differences
between the experimental groups. Data were expressed as
mean± standard deviation (SD).
4. Results
4.1. Effect of SDF-1 Treatment on Cell Proliferation in Spinal Cord
Injury
The BrdU positive cells were absent in the spinal cord of
sham operated animals, whereas many proliferating cells
could be observed after spinal cord contusion injury in
other groups (Figure 1). Interestingly, numbers of BrdU
positive cells were significantly higher in the SDF-1a group.
No difference was observed in the number of BrdU positive
cells between vehicle and SCI groups in the contusion re-
gions (Figure 1E).
4.2. Real Time Polymerase Chain Reaction
Result showed that the expression of CXCR4 in the
SDF-1 group was significantly more than other groups (P
< 0.001). No difference was observed in the expression of
CXCR4 between SCI and vehicle groups (P > 0.05) (Figure
2).
4.3. Locomotor Function
The BBB rating scale was performed within five weeks
after surgery. There was no significant difference in BBB
score during the first week between injured groups but as
shown in Figure 3, after the third week BBB rating scale in
the SDF-1 group was significantly higher (10-12) than the SCI
and vehicle groups (P < 0.05). These animals were capable
of active motility, which revealed that the rats could sup-
port weight walking and that forelimb and hind limb co-
ordination ability was good. However, the SCI and vehicle
groups achieved a mean BBB score of eight.
5. Discussion
The results of the present study provide evidence that
intrathecal SDF-1 improves movement and increases prolif-
eration of cells in the SCI region in rats.
Stromal Cell-Derived Factor-1 is one member of the
chemokine family that causes movement and migration of
cells from bone marrow via CXCR4 (8, 17-19). The SDF1, af-
ter binding to CXCR4, regulates some biological activity in
CXCR4-positive cells such as: cell growth, proliferation and
angiogenesis (6). Transgenic mice with mutations in SDF1
and CXCR4 gene phenotypes had some abnormalities in
their central nervous system and heart (20). Stromal Cell-
Derived Factor-1 is secreted from many tissues of the body
and is found in organs such as the heart, kidneys, brain,
liver, spleen and lungs (21, 22). In CNS, this chemokine is re-
leased from microglia, astrocyte and neurons (23, 24). Fol-
lowing CNS injury, the rising of SDF-1 levels is mostly asso-
ciated with astrocytes and attracts immune and stem cells
towards the injury site (6, 25).
There is a physiological dose of SDF-1 in CNS yet in
pathologic conditions such as ischemia or injury, glial cells
are activated and a large amount is secreted (26).
Furthermore, CXCR4 is expressed in many types of
body cells such as lymphocytes, monocytes, neutrophil,
epithelial, microglial, endothelial, bone marrow stromal
cells, Neural Stem Cells (NSC) and embryonic-like stem
cells (27-29). It was demonstrated that SDF1 is involved in
migration of NSCs to the injury site of the brain (30-32).
Wang et al. showed that SDF-1α/CXCR4-mediated mi-
gration of systemically transplanted bone marrow stromal
cells towards ischemic brain lesion in a rat model (33).
Hill et al. demonstrated that the expression of SDF-1a
and its receptor is increased at sites of neuronal injury (26).
Another study indicated that inhibition of SDF-1 by ap-
plication of neutralizing antibodies in vivo resulted in a
significantly reduced number of human umbilical cord
blood cells at the lesion area (34).
The results of real-time PCR of CXCR4 gene in all groups
in our study demonstrated that SDF1 attracted CXCR4 cells
to the site of the injury; these CXCR4 cells in the SDF-1 group
were higher than those in SCI and vehicle groups.
Zededel et al. showed that the number of caspase pos-
itive cells decreased and proliferating cells increased dose
dependently in the SCI region in rats, which received SDF-1
(5).
In the present study, Brdu-positive cell counting at the
spinal cord injury site, number of proliferative cells, in-
creased after injection of SDF-1, which is in agreement with
the mentioned studies.
Another finding of our study was the improvement of
BBB rating score in SDF-1 group compared to the SCI and ve-
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Figure 1. The Effects of Stromal Cell-Derived Factor-1 Administration on the Number of Proliferative Bromodeoxyuridine Positive Cells
SDF-1
A, Sham group; B, SCI group; C, SDF-1 group; D, vehicle group (10×); E, the graph shows proliferative cell count in all groups. The Brdu positive cells in the SDF-1 group were
significantly more than the SCI and vehicle groups. Data are expressed as mean± SD; *P < 0.001 compare to Sham group; ** P < 0.001 compare to SCI and vehicle group.
hicle groups, this difference was markedly higher at three to five weeks in the SDF-1 group than the SCI and vehicle
4 Gene Cell Tissue. 2016; 3(2):e36386.
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Figure 2. Percentage of CXC Chemokine Receptor 4 Relative Gene Expression in All
Groups
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CXCR4-gene expression was significantly higher than the vehicle group (mean ±
SD);*P < 0.001 compared to the vehicle and SCI group.
Figure 3. Basso, Beattie and Bresnahan (BBB) Locomotion Rating Scale During Five
Weeks After Injury and Receiving Stromal Cell-Derived Factor-1
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BBB score after the third week in the SDF-1 group (12) was significantly higher than
the vehicle and SCI groups (8). Data are expressed as mean± SD; *P < 0.05 compared
to the vehicle group.
groups.
A recent study indicated that erythropoietin mobilizes
BMSCs to the lesion site following SCI, enhances the anti-
apoptotic effects of BMSCs by up-regulating the expression
of the SDF-1/CXCR4 axis and improves neurological out-
comes following SCI (8).
In another study, it was shown that chronic administra-
tion of SDF-1 1000 mg/mL in SCI rats improved behavioral
scores compared to the control group (3). These findings
are in agreement with our study. Higher numbers of Brdu-
positive cells, CXCR4 expression and higher score of BBB in
the SDF-1 group in our study indicated that SDF- 1 have neu-
roprotective effects in this animal model (35).
This means SDF1 induced migration of CXCR4 cells at
the injury site and induced cell proliferation and secretion
of some neurotrophic factors that limited damage at the
injury site.
5.1. Conclusions
The results of the present study showed that intrathe-
cal administration of SDF-1 increases the CXCR4 cells at
the injury site and consequently improves movement in
SCI rats, therefore SDF-1 might be a therapeutic option in
spinal cord injury, although more research is required in
order to elucidate the potential therapeutic role of SDF-1 in
SCI recovery.
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